Needa Brown

Sponsor: DFCI

STING agonist drug delivery formulations synergize with PARPi to treat resistant, metastatic advanced breast cancer

The objective of this work is to generate clinically relevant data to support the use of PARPi in combination with local and systemic drug delivery platforms of STING agonists in order to treat metastatic, resistant breast cancer.